Sight Sciences has enrolled the first subject in the OLYMPIA pivotal trial of TearCare for dry eye disease, the company announced in a press release.
TearCare is a wearable, personalized, open-eye technology that delivers regulated, localized heat to the eyelids. The prospective, multicenter, randomized OLYMPIA study will evaluate TearCare compared with LipiFlow (Johnson & Johnson Vision) in 138 subjects with meibomian gland dysfunction, the release said.
“Our team has worked diligently over the past 6 years to design a system that is intended to set a new bar for dry eye therapy. This trial brings us one step closer to our vision of delivering a better dry eye treatment experience for both patients and eye care professionals,” Paul Badawi, co-founder and CEO of Sight Sciences, said in the release.